Pharmacokinetics of 5,6-trans-25-hydroxycholecalciferol, a synthetic analogue of vitamin D3, in man.
Vitamin D analogues of high biological activity are probably useful in the treatment of renal osteodystrophy. The pharmacokinetics of the synthetic compound 5,6-trans-25-hydroxycholecalciferol have been studied in healthy subjects who were of normal vitamin D status. In comparison to natural 25-hydroxy-cholecalciferol, serum levels of the analogue were lower and its half-life in blood after oral or intravenous administration was considerably shorter. In normal subjects no increase of dihydroxylated metabolites in serum was observed within seven days of an intravenous dose.
D000284:Administration, Oral; D000328:Adult; D005260:Female; D006207:Half-Life; D006801:Humans; D006887:Hydroxycholecalciferols / Q000008:administration & dosage / Q000097:blood*; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D008954:Models, Biological
D006887:Hydroxycholecalciferols